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Summary 
 
Objective: To assess the advantages and disadvantages of using Letrozole for 
controlled ovarian stimulation (COH) in young patients with estrogen receptor-
positive (ER+) breast cancer, wishing to cryopreserve oocytes. 
Design: Retrospective cohort analysis. 
Setting: Sixteen Italian Units for Reproductive Medicine and In Vitro Fertilization. 
Methods: Data of 50 ER+ breast cancer patients undergoing COH  to cryopreserve 
oocytes before gonadotoxic chemotherapy with a Letrozole plus gonadotropins 
(Le+Gn) protocol were compared with those of 25 young women with ER- breast 
cancer, submitted to COH using a protocol with gonadotropins alone (Gn-only).  
Results: The Le+Gn protocol implied a significantly lower total Gn consumption and 
allowed to maintain significantly lower circulating E2 levels at all checkpoints 
throughout stimulation (peak E2 value  446 ± 357 vs.1553 ± 908 pg/ml, respectively; 
p=0.001). On the other side, the Le+Gn protocol allowed a significantly lower yield of 
oocytes available for cryostorage (6.6 ± 3.5 vs. 8 ± 5, respectively; p=0.038)..   
Conclusions: In breast cancer patients, the association of Letrozole to Gn 
significantly reduces the number of oocytes available for cryostorage in comparison 
with the use of Gn alone. On the other side, it is associated with significantly lower 
E2 levels during the whole stimulation cycle, a safety issue that has been traditionally 
considered advantageous in case of ER+ cancers.  
 
 
 
Introduction  
Fertility preservation is an important issue for young women affected by cancer, 
Among malignancies that affect women in the fertile age, breast cancer is one of the 
most frequent; more and more frequently these patients ask to be submitted to 
controlled hormonal ovarian stimulation (COH) in order to retrieve and cryostore 
oocytes (1-3).  
The available laboratory techniques to freeze and store human oocytes  have 
reached a high effectiveness in maintaining oocyte viability and competence, 
However the number of eggs that are cryostored is  still a critical issue in determining 
the chance of having a baby  after cancer expecially when the slow freezing 
technique is applied (4) . On the other side, when the patient is affected by an 
estrogen-receptor positive (ER+) cancer, COH  cannot be aimed exclusively at 
retrieving the highest number of eggs, but must even expose to the lowest possible 
levels of estrogens (5). 
Due to its property of keeping low estradiol (E2) levels during COH, the aromatase 
inhibitor Letrozole has been proposed in association to Gn for oocyte harvesting in 
patients with E2-sensitive malignancies (6-8,11) cancer. The effectiveness of 
Letrozole for COH has been evaluated mainly in non-oncological patients with 
polycystic ovary (PCO) (12, 13), but only a few reports have studied its effectiveness 
in women with normal ovaries (14-16).  
Our study is the first to evaluate the association Letrozole-plus-Gn (Le+Gn protocol) 
in comparison with the classical COH with Gn alone (Gn-only protocol) in an 
homogeneous cohort of young women, all affected by breast cancer. We conducted 
a multicenter retrospective analysis specifically focusing on two objectives: a) the 
protocol effectiveness in terms of oocyte retrieval and availability of eggs for 
cryopreservation, and b) the circulating E2 levels during COH. 
 Materials and Methods  
Patients 
Among Italian in vitro fertilization (IVF) Units that routinely use oocyte freezing for IVF 
patients, sixteen accepted to participate; they cryopreserved oocytes in breast cancer 
patients during the time period December 2000 - January 2012.  
Overall, a total number of 75 young women affected by breast cancer (1-19 per IVF 
Unit) were included in the study; each patient was submitted to a single cycle of COH 
aimed at obtaining oocytes for fertility preservation. The patients’ basal 
characteristics are shown in Table 1.  
Table 1. Patients’ clinical characteristics. Data are expressed as mean±SD. 
 Le-Gn  
(n=50) 
Gn-only  
(n=25) 
 
P 
Age  (years) 34.4 ± 5.2  35.1 ± 4.9  ns 
Patients aged ≥ 38 yrs (%) 26 36 ns 
Patients with children (%) 7.5 5.2 ns 
Patients with previous infertility (%) 5.8 11.5 ns 
Patients with previous ovarian surgery (%) 6.8 8.6 ns 
Smokers (%) 19 5.2 ns 
BMI  21.8 ± 3 20 ± 1.9 ns 
Basal  FSH (IU/L) 7.3 ± 2.7 7.8 ± 3 ns 
AMH (ng/ml) 3.9 ± 2.6 4.1 ± 3 ns 
Antral Follicle Count (AFC) 10 ± 5.5 12 ± 9.9 ns 
 
When the breast cancer was ER+ (50 patients), Letrozole was added to Gn, and the 
Le+Gn protocol was used; on the contrary, when the cancer was ER- (25 patients), 
only gonadotropins (Gn-only protocol) were administered. The latter patients were 
used as a control group to assess the effects of Letrozole on COH.  
 
Ovarian stimulation regimens 
The ovarian Le+Gn stimulation (50 COH cycles) was accomplished with an 
antagonist protocol as described by Oktay starting always in the early follicular 
phase(8-9) The Gn-only stimulation regimen (25 cycles) was performed 
administering subcutaneous Gn (recombinant FSH or hMG) from cycle day 2 with an 
antagonist protocol or with a long GnRH agonists protocol. The Gn starting dose was 
chosen for each patient on the basis of the following clinical characteristics: age, 
body mass index, basal (day 3) FSH level, anti-mullerian hormone level, antral follicle 
count, and was then adjusted according to ovarian response. Recombinant FSH (rec-
FSH; Gonal F, Merck-Serono, Geneva, Switzerland, or Puregon, MSD, Whitehouse 
Station, NJ, USA) was used in most stimulation cycles (82% in the Le+Gn group and 
92% in the Gn-only group, respectively), whereas human menopausal gonadotropins 
(hMG; Ferring, Darmstadt, Germany) was used in 18% of cycles in the Le+Gn group 
and in 8% of cycles in the Gn-only group.  
Ovarian stimulation was monitored by serial transvaginal ultrasound (US) 
examinations coupled to serum E2 measurements starting on stimulation day 5-8. 
When appropriate according to ovarian US and E2 levels, 10,000 IU of hCG (Gonasi 
HP, IBSA, Lugano, Switzerland) were administered and oocyte pick-up (OPU) was 
performed 35-37 hours later under US guidance. The retrieved oocytes were 
immediately observed to assess nuclear maturity, and metaphase II eggs were 
cryostored; the slow-freezing or the vitrification techniques (17) were used in 70% 
and 30% of cases, respectively. 
 
End points and statistics 
The primary end-points of the present study were: a) the number of mature, 
cryopreservable oocytes, and b) E2 levels during stimulation. Secondary end-points 
were the following: proportion of cancelled cycles, total amount of administered Gn, 
stimulation length, E2/retrieved and E2/cryopreserved oocyte ratios. 
The Chi square test statistics was used to compare categorical covariates, and 
continuity correction was used to account for small expected observations. The mean 
levels of the studied covariates was tested by means of the Student t test or the 
Welch test according to the results of Levene's test for equality of variance. 
Differences were considered statistically significant at an α level <0.05. 
 
Results 
The two groups of patients did not significantly differ for any of the basal clinical 
characteristics (Table 1).  
Overall, four cycles out of 75 were cancelled before OPU, one in the Le+Gn group 
and three in the Gn-only group; however, only one cycle in the Gn-only group was 
cancelled for inadequate ovarian response (Table 2), whereas the others were 
stopped for sudden health problems that forced to anticipate the oncological 
treatment, unrelated to the stimulation itself.  
The starting Gn dose and the total dose of administered Gn were significantly lower 
in the Le+Gn than in the Gn-only group (Table 2).The number of developing follicles 
was similar with both protocols, but the number of oocytes retrieved was borderline 
significant in favor of Gn-only regimen and the number of mature oocytes available 
for cryopreservation(6.6 ± 3.5 vs. 8 ± 5; p=0.038) was significantly higher in the Gn-
only group (Table 2). 
The anti-estrogenic effect of Letrozole resulted in significantly lower E2 levels at all 
checkpoints during stimulation (Figure 1). The peak E2 level the day of hCG 
administration (D-hCG) was approximately one third in the Le+Gn group than in the 
Gn-only group (Table 2).  
Discussion 
The property of stimulating follicular recruitment and growth while keeping low E2 
levels renders Letrozole particularly interesting for young women with E2-sensitive 
malignancies (e.g., endometrial and ER+ breast cancers) wishing to preserve their 
fertility by COH followed by oocyte or, whenever legal, embryo cryostorage (6-11, 
18). On the other side  the number of oocytes available for freezing is a key issue in 
determining the chances to preserve fertility especially with the slow –freezing 
technique, which was applied in the majority of cases in this studyOktay (18) reported 
a better oocytes recovery with the Le+Gn protocol compared with Tamoxifen-alone 
and Tamoxifen-plus-Gn in breast cancer patients. However a lower number of 
retrieved oocytes was observed in Le+Gn-stimulated breast cancer patients 
compared with Gn-only-stimulated healthy controls (8), and in Le+Gn-stimulated  
breast cancer patients compared with women with hormonal-independent cancers 
stimulated by Gn alone (19).  
Our study is the first in which the Le+Gn stimulation regimen is compared with a Gn-
only COH regimen in an homogeneous group of young women affected by breast 
cancer, among which the ER- subjects, stimulated by Gn-only, represent the control 
group.  
The technical experience with oocyte freezing in Italy is one of the widest in the world 
(20-24) and oocyte freezing is frequently offered to oncological patients. We 
observed that the number of mature and oocytes, was significantly (about 40%) lower 
when Letrozole was used (Table 2). Although an early timing of hCG administration 
as been held responsible  for the higher percentage of immature oocytes in letrozole 
stimulation (8), in this study also the overall number of retrived oocytes was lower in 
patients than in controls stimulated without Letrozole.Indeed the number of oocytes 
obtained in our study by the Le+Gn regimen was lower than previously published (8, 
19), suggesting a more cautious attitude for COH in Italy and/or a higher proportion 
of poorly-responding women among Italian patients. It must be remarked, in fact, that 
about one third of the patients included in our survey was older than 38 at the time of 
stimulation. the different proportion of smokers in Le-Gn and Gn-only groups and the different 
number of cycles receiving HMG instead of recFSH may have contributed to a lower ovarian 
response acting as confounders on the role of letrozole.” 
Above all  a  possible reason why in our study the oocyte yield was lower when 
Letrozole was used is that both the Gn starting and the Gn total doses were 
significantly lower in the Le+Gn group than in the Gn-only group (Table 2). Anyway, it 
was reported that increasing the Gn dose associated with Letrozole is not effective in 
enhancing oocyte yield (25); thus, the lower dose of Gn should not be responsible for 
the reduced oocyte yield. Alternatively, instead, it could be due to a lower ovarian 
responsiveness of patients with ER+ cancers in comparison to women with E2-
insensitive tumors, that was reported by some (26), but not by others (27). 
The number of oocytes available for freezing is indeed very important, but dealing 
with E2-sensitive cancers, the patient’s exposure to E2 is another major issue. 
Estrogens are known to actively stimulate the proliferation of ER+ breast cancer cells 
(28,29). Until the recent past, ovarian stimulation for fertility sparing was forbidden for 
women with E2-sensitive cancers because of the fear of the stimulating effect of E2 
on cancer progression. Indeed Letrozole-including protocols have been proposed for 
cancer patients just with the scope of overcoming this limitation and have been  
associated with a comparable cancer recurrence rate to that observed for breast 
cancer patients who were not willing to cryopreserve and did not undergo ovarian 
stimulation (7).  
Our study clearly shows that the use of the Le+Gn protocol implies a significantly 
lower E2 levels from the first checkpoint (day 5-8 of the stimulation cycle), throughout 
the whole stimulation cycle, until the day in which hCG was administered  (D-hCG; 
Figure 1).  
Moreover, we observed a significantly lower E2/oocyte ratio with the Le+Gn regimen, 
witnessing the lower E2 amount produced by each single developing follicle (Table 
2). The observed reduction in circulating E2 in women who received Letrozole was 
very relevant - approximately 70% - compared to E2 levels observed in patients 
receiving Gn-only. Is the fear of worsening the prognosis of ER+ breast cancer 
patients performing a “classical” COH with Gn-only justified?  Indeed it appears to be 
based on rather uncertain scientific data for at least two reasons: (a) it is unknown to 
which extent a short (some days) exposure to high E2 levels can affect the global 
prognosis of a woman with an ER+ breast cancer (5), and (b) it is unknown which 
concentration of E2 is needed to significantly accelerate ER+ breast cancer cells 
proliferation. On one side Letrozole administration seems reasonable in order to 
expose ER+ breast cancer patients to the lowest E2 levels possible, on the other side 
it appears questionable. Is it correct (and ethical) to apply a COH protocol that is 
known to have a lower chance to preserve fertility (significantly less cryopreservable 
oocytes) to avoid a possible risk of harmful effects of elevated circulating E2 levels? 
These effects have not been precisely quantified and could also be elicited by much 
lower E2 levels, e.g. those reached during Le+Gn COH.   
With the limits of its retrospective and multicentre nature, the present study shows 
that in breast cancer patients the Le+Gn stimulation protocol implies a lower 
availability of cryopreservable oocytes than the classical Gn-only regimen, and 
implies a significantly lower E2 exposure. Our observations do not allow to assess if 
the Le+Gn protocol is the best available option for ER+ breast cancer patients, a 
satisfactory compromise between safety and effectiveness. Further studies aimed at 
precisely assessing the impact of a short and limited E2 exposure on the kinetics of 
breast cancer cells and on the prognosis of premenopausal ER+ breast cancer will 
help to give a definite answer to this issue. 
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